nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—nephrolithiasis	0.858	1	CtDrD
Pazopanib—STK10—renal vein—nephrolithiasis	0.0144	0.191	CbGeAlD
Pazopanib—STK10—renal artery—nephrolithiasis	0.00967	0.128	CbGeAlD
Pazopanib—Localised oedema—Hydrochlorothiazide—nephrolithiasis	0.00401	0.0927	CcSEcCtD
Pazopanib—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.00335	0.0775	CcSEcCtD
Pazopanib—UGT1A1—urine—nephrolithiasis	0.00256	0.034	CbGeAlD
Pazopanib—Sinus bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00207	0.0477	CcSEcCtD
Pazopanib—Encephalopathy—Hydrochlorothiazide—nephrolithiasis	0.00158	0.0365	CcSEcCtD
Pazopanib—SH2B3—nephron tubule—nephrolithiasis	0.00152	0.0201	CbGeAlD
Pazopanib—TAOK1—renal system—nephrolithiasis	0.00147	0.0195	CbGeAlD
Pazopanib—TAOK1—cortex of kidney—nephrolithiasis	0.00138	0.0183	CbGeAlD
Pazopanib—SH2B3—cortex of kidney—nephrolithiasis	0.0013	0.0172	CbGeAlD
Pazopanib—RIOK2—nephron tubule—nephrolithiasis	0.00127	0.0169	CbGeAlD
Pazopanib—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00123	0.0285	CcSEcCtD
Pazopanib—FGFR3—renal system—nephrolithiasis	0.00115	0.0153	CbGeAlD
Pazopanib—CYP1A2—urine—nephrolithiasis	0.00113	0.015	CbGeAlD
Pazopanib—PI4KB—nephron tubule—nephrolithiasis	0.00112	0.0149	CbGeAlD
Pazopanib—FGFR3—kidney—nephrolithiasis	0.00112	0.0148	CbGeAlD
Pazopanib—FGFR3—cortex of kidney—nephrolithiasis	0.00109	0.0144	CbGeAlD
Pazopanib—RIOK2—cortex of kidney—nephrolithiasis	0.00109	0.0144	CbGeAlD
Pazopanib—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00103	0.0237	CcSEcCtD
Pazopanib—PI4KB—renal system—nephrolithiasis	0.00102	0.0136	CbGeAlD
Pazopanib—PI4KB—kidney—nephrolithiasis	0.000988	0.0131	CbGeAlD
Pazopanib—PIP4K2C—nephron tubule—nephrolithiasis	0.000986	0.0131	CbGeAlD
Pazopanib—STK36—cortex of kidney—nephrolithiasis	0.000977	0.013	CbGeAlD
Pazopanib—PI4KB—cortex of kidney—nephrolithiasis	0.000962	0.0128	CbGeAlD
Pazopanib—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.000956	0.0221	CcSEcCtD
Pazopanib—LIMK2—cortex of kidney—nephrolithiasis	0.000944	0.0125	CbGeAlD
Pazopanib—MAP3K2—nephron tubule—nephrolithiasis	0.000935	0.0124	CbGeAlD
Pazopanib—FGF1—nephron tubule—nephrolithiasis	0.000881	0.0117	CbGeAlD
Pazopanib—FLT4—cortex of kidney—nephrolithiasis	0.000849	0.0113	CbGeAlD
Pazopanib—PIP4K2C—cortex of kidney—nephrolithiasis	0.000844	0.0112	CbGeAlD
Pazopanib—FGFR1—cortex of kidney—nephrolithiasis	0.000837	0.0111	CbGeAlD
Pazopanib—CYP3A4—urine—nephrolithiasis	0.000821	0.0109	CbGeAlD
Pazopanib—CYP2D6—urine—nephrolithiasis	0.000807	0.0107	CbGeAlD
Pazopanib—FGF1—renal system—nephrolithiasis	0.000801	0.0106	CbGeAlD
Pazopanib—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.000786	0.0182	CcSEcCtD
Pazopanib—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.000779	0.018	CcSEcCtD
Pazopanib—FGF1—kidney—nephrolithiasis	0.000774	0.0103	CbGeAlD
Pazopanib—FLT1—nephron tubule—nephrolithiasis	0.000771	0.0102	CbGeAlD
Pazopanib—FGFR2—renal system—nephrolithiasis	0.000756	0.01	CbGeAlD
Pazopanib—FGF1—cortex of kidney—nephrolithiasis	0.000754	0.01	CbGeAlD
Pazopanib—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.000738	0.0171	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.000735	0.017	CcSEcCtD
Pazopanib—FGFR2—kidney—nephrolithiasis	0.000731	0.0097	CbGeAlD
Pazopanib—TAOK3—nephron tubule—nephrolithiasis	0.000727	0.00965	CbGeAlD
Pazopanib—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00071	0.0164	CcSEcCtD
Pazopanib—FLT1—renal system—nephrolithiasis	0.000701	0.0093	CbGeAlD
Pazopanib—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.000689	0.0159	CcSEcCtD
Pazopanib—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.000679	0.0157	CcSEcCtD
Pazopanib—FLT1—kidney—nephrolithiasis	0.000677	0.00899	CbGeAlD
Pazopanib—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.000674	0.0156	CcSEcCtD
Pazopanib—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.000671	0.0155	CcSEcCtD
Pazopanib—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.000664	0.0154	CcSEcCtD
Pazopanib—STK10—renal system—nephrolithiasis	0.000663	0.00881	CbGeAlD
Pazopanib—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000662	0.0153	CcSEcCtD
Pazopanib—TAOK3—renal system—nephrolithiasis	0.000661	0.00877	CbGeAlD
Pazopanib—FLT1—cortex of kidney—nephrolithiasis	0.00066	0.00876	CbGeAlD
Pazopanib—PDGFRA—renal system—nephrolithiasis	0.000657	0.00872	CbGeAlD
Pazopanib—EPHB6—cortex of kidney—nephrolithiasis	0.000652	0.00866	CbGeAlD
Pazopanib—KDR—nephron tubule—nephrolithiasis	0.000652	0.00865	CbGeAlD
Pazopanib—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000648	0.015	CcSEcCtD
Pazopanib—STK10—kidney—nephrolithiasis	0.000641	0.00851	CbGeAlD
Pazopanib—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00064	0.0148	CcSEcCtD
Pazopanib—TAOK3—kidney—nephrolithiasis	0.000639	0.00848	CbGeAlD
Pazopanib—UGT1A1—renal system—nephrolithiasis	0.000626	0.00832	CbGeAlD
Pazopanib—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000623	0.0144	CcSEcCtD
Pazopanib—TAOK3—cortex of kidney—nephrolithiasis	0.000622	0.00826	CbGeAlD
Pazopanib—UGT1A1—kidney—nephrolithiasis	0.000606	0.00804	CbGeAlD
Pazopanib—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.000594	0.0137	CcSEcCtD
Pazopanib—KDR—renal system—nephrolithiasis	0.000592	0.00786	CbGeAlD
Pazopanib—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00058	0.0134	CcSEcCtD
Pazopanib—KIT—nephron tubule—nephrolithiasis	0.000578	0.00767	CbGeAlD
Pazopanib—KDR—kidney—nephrolithiasis	0.000573	0.0076	CbGeAlD
Pazopanib—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.000558	0.0129	CcSEcCtD
Pazopanib—KDR—cortex of kidney—nephrolithiasis	0.000558	0.0074	CbGeAlD
Pazopanib—MAP2K5—cortex of kidney—nephrolithiasis	0.000558	0.0074	CbGeAlD
Pazopanib—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.000555	0.0128	CcSEcCtD
Pazopanib—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.000552	0.0128	CcSEcCtD
Pazopanib—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00054	0.0125	CcSEcCtD
Pazopanib—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.000534	0.0124	CcSEcCtD
Pazopanib—KIT—renal system—nephrolithiasis	0.000525	0.00697	CbGeAlD
Pazopanib—SLCO1B1—renal system—nephrolithiasis	0.000521	0.00692	CbGeAlD
Pazopanib—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.000518	0.012	CcSEcCtD
Pazopanib—PDGFRB—renal system—nephrolithiasis	0.000513	0.00681	CbGeAlD
Pazopanib—KIT—kidney—nephrolithiasis	0.000508	0.00674	CbGeAlD
Pazopanib—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.000506	0.0117	CcSEcCtD
Pazopanib—SLCO1B1—kidney—nephrolithiasis	0.000504	0.00669	CbGeAlD
Pazopanib—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.000501	0.0116	CcSEcCtD
Pazopanib—PDGFRB—kidney—nephrolithiasis	0.000496	0.00658	CbGeAlD
Pazopanib—KIT—cortex of kidney—nephrolithiasis	0.000494	0.00656	CbGeAlD
Pazopanib—PDGFRB—cortex of kidney—nephrolithiasis	0.000483	0.00641	CbGeAlD
Pazopanib—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000472	0.0109	CcSEcCtD
Pazopanib—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.000449	0.0104	CcSEcCtD
Pazopanib—Erythema—Hydrochlorothiazide—nephrolithiasis	0.000443	0.0102	CcSEcCtD
Pazopanib—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000436	0.0101	CcSEcCtD
Pazopanib—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000434	0.01	CcSEcCtD
Pazopanib—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.000426	0.00984	CcSEcCtD
Pazopanib—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000417	0.00965	CcSEcCtD
Pazopanib—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000409	0.00946	CcSEcCtD
Pazopanib—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000397	0.00918	CcSEcCtD
Pazopanib—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.000396	0.00916	CcSEcCtD
Pazopanib—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000389	0.009	CcSEcCtD
Pazopanib—Cough—Hydrochlorothiazide—nephrolithiasis	0.000386	0.00893	CcSEcCtD
Pazopanib—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.000377	0.00871	CcSEcCtD
Pazopanib—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000377	0.00871	CcSEcCtD
Pazopanib—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000377	0.00871	CcSEcCtD
Pazopanib—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000369	0.00852	CcSEcCtD
Pazopanib—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000361	0.00835	CcSEcCtD
Pazopanib—Shock—Hydrochlorothiazide—nephrolithiasis	0.000355	0.00822	CcSEcCtD
Pazopanib—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.000354	0.00818	CcSEcCtD
Pazopanib—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.000349	0.00808	CcSEcCtD
Pazopanib—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000344	0.00796	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000329	0.00761	CcSEcCtD
Pazopanib—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000327	0.00756	CcSEcCtD
Pazopanib—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000324	0.0075	CcSEcCtD
Pazopanib—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000322	0.00745	CcSEcCtD
Pazopanib—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000321	0.00743	CcSEcCtD
Pazopanib—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000318	0.00735	CcSEcCtD
Pazopanib—ABCG2—nephron tubule—nephrolithiasis	0.000317	0.00421	CbGeAlD
Pazopanib—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000314	0.00726	CcSEcCtD
Pazopanib—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000312	0.0072	CcSEcCtD
Pazopanib—Pain—Hydrochlorothiazide—nephrolithiasis	0.000309	0.00714	CcSEcCtD
Pazopanib—CYP2C8—renal system—nephrolithiasis	0.000296	0.00393	CbGeAlD
Pazopanib—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000295	0.00683	CcSEcCtD
Pazopanib—CYP2C8—kidney—nephrolithiasis	0.000287	0.0038	CbGeAlD
Pazopanib—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000286	0.0066	CcSEcCtD
Pazopanib—CYP1A2—renal system—nephrolithiasis	0.000277	0.00368	CbGeAlD
Pazopanib—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000259	0.00599	CcSEcCtD
Pazopanib—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000256	0.00591	CcSEcCtD
Pazopanib—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000247	0.00572	CcSEcCtD
Pazopanib—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000239	0.00552	CcSEcCtD
Pazopanib—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00023	0.00531	CcSEcCtD
Pazopanib—Rash—Hydrochlorothiazide—nephrolithiasis	0.000228	0.00527	CcSEcCtD
Pazopanib—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000228	0.00526	CcSEcCtD
Pazopanib—Headache—Hydrochlorothiazide—nephrolithiasis	0.000226	0.00523	CcSEcCtD
Pazopanib—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000215	0.00496	CcSEcCtD
Pazopanib—CYP3A4—renal system—nephrolithiasis	0.000201	0.00266	CbGeAlD
Pazopanib—CYP2D6—renal system—nephrolithiasis	0.000198	0.00262	CbGeAlD
Pazopanib—CYP3A4—kidney—nephrolithiasis	0.000194	0.00258	CbGeAlD
Pazopanib—CYP2D6—kidney—nephrolithiasis	0.000191	0.00254	CbGeAlD
Pazopanib—PDGFRB—Beta3 integrin cell surface interactions—SPP1—nephrolithiasis	0.000174	0.00747	CbGpPWpGaD
Pazopanib—FGFR2—FGF signaling pathway—SPP1—nephrolithiasis	0.000173	0.00743	CbGpPWpGaD
Pazopanib—FGFR2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000167	0.00718	CbGpPWpGaD
Pazopanib—SLCO1B1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000166	0.00713	CbGpPWpGaD
Pazopanib—SLCO1B1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000166	0.00713	CbGpPWpGaD
Pazopanib—FGFR1—FGF signaling pathway—SPP1—nephrolithiasis	0.000161	0.00692	CbGpPWpGaD
Pazopanib—PI4KB—Metabolism—AGXT—nephrolithiasis	0.000159	0.00684	CbGpPWpGaD
Pazopanib—ABCB1—nephron tubule—nephrolithiasis	0.000156	0.00208	CbGeAlD
Pazopanib—FGFR1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000156	0.0067	CbGpPWpGaD
Pazopanib—PDGFRA—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000155	0.00668	CbGpPWpGaD
Pazopanib—MAP3K2—BDNF signaling pathway—SPP1—nephrolithiasis	0.000155	0.00666	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—ADCY10—nephrolithiasis	0.000143	0.00615	CbGpPWpGaD
Pazopanib—ABCB1—renal system—nephrolithiasis	0.000142	0.00189	CbGeAlD
Pazopanib—FGFR1—Endochondral Ossification—SPP1—nephrolithiasis	0.000141	0.00604	CbGpPWpGaD
Pazopanib—PDGFRB—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00014	0.00602	CbGpPWpGaD
Pazopanib—LYN—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000138	0.00594	CbGpPWpGaD
Pazopanib—ABCB1—kidney—nephrolithiasis	0.000137	0.00182	CbGeAlD
Pazopanib—PI4KB—Metabolism—APRT—nephrolithiasis	0.000135	0.00582	CbGpPWpGaD
Pazopanib—PI4KB—Metabolism—SLC26A1—nephrolithiasis	0.000135	0.00582	CbGpPWpGaD
Pazopanib—ABCB1—cortex of kidney—nephrolithiasis	0.000134	0.00178	CbGeAlD
Pazopanib—FLT4—Signaling Pathways—ADCY10—nephrolithiasis	0.000131	0.00563	CbGpPWpGaD
Pazopanib—SLCO1B1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000126	0.0054	CbGpPWpGaD
Pazopanib—SLCO1B1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000126	0.0054	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—RGS14—nephrolithiasis	0.000122	0.00523	CbGpPWpGaD
Pazopanib—FLT1—Focal Adhesion—SPP1—nephrolithiasis	0.00012	0.00517	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—DGKH—nephrolithiasis	0.000119	0.0051	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000119	0.0051	CbGpPWpGaD
Pazopanib—SLCO1B1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000117	0.00502	CbGpPWpGaD
Pazopanib—SLCO1B1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000117	0.00502	CbGpPWpGaD
Pazopanib—LCK—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000113	0.00487	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—RGS14—nephrolithiasis	0.000111	0.00478	CbGpPWpGaD
Pazopanib—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.000111	0.00477	CbGpPWpGaD
Pazopanib—SLCO1B1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000104	0.00448	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000103	0.00444	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000103	0.00444	CbGpPWpGaD
Pazopanib—MAP2K5—BDNF signaling pathway—SPP1—nephrolithiasis	0.000103	0.00441	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—ADCY10—nephrolithiasis	9.77e-05	0.0042	CbGpPWpGaD
Pazopanib—PI4KB—Metabolism—AQP1—nephrolithiasis	9.64e-05	0.00414	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	9.57e-05	0.00411	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	9.57e-05	0.00411	CbGpPWpGaD
Pazopanib—FGFR3—Signaling by PDGF—SPP1—nephrolithiasis	9.51e-05	0.00409	CbGpPWpGaD
Pazopanib—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	9.34e-05	0.00402	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	9.21e-05	0.00396	CbGpPWpGaD
Pazopanib—PI4KB—Metabolism—CHRM3—nephrolithiasis	8.72e-05	0.00375	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—CHRM3—nephrolithiasis	8.58e-05	0.00369	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	8.53e-05	0.00367	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	8.43e-05	0.00362	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	8.43e-05	0.00362	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—RGS14—nephrolithiasis	8.31e-05	0.00357	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—DGKH—nephrolithiasis	8.22e-05	0.00353	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	8.22e-05	0.00353	CbGpPWpGaD
Pazopanib—MAP2K5—Focal Adhesion—SPP1—nephrolithiasis	8.21e-05	0.00353	CbGpPWpGaD
Pazopanib—KDR—Focal Adhesion—SPP1—nephrolithiasis	8e-05	0.00344	CbGpPWpGaD
Pazopanib—FGF1—Signaling by PDGF—SPP1—nephrolithiasis	7.9e-05	0.0034	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—PTH—nephrolithiasis	7.84e-05	0.00337	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	7.8e-05	0.00335	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	7.8e-05	0.00335	CbGpPWpGaD
Pazopanib—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	7.67e-05	0.0033	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—ATP6V0A4—nephrolithiasis	7.52e-05	0.00323	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—DGKH—nephrolithiasis	7.52e-05	0.00323	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—ADCY10—nephrolithiasis	7.46e-05	0.00321	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—SLC7A9—nephrolithiasis	7.13e-05	0.00306	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—DGKH—nephrolithiasis	7.13e-05	0.00306	CbGpPWpGaD
Pazopanib—FGFR3—Disease—SLC26A1—nephrolithiasis	6.87e-05	0.00295	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—ADCY10—nephrolithiasis	6.67e-05	0.00287	CbGpPWpGaD
Pazopanib—FGFR2—Signaling by PDGF—SPP1—nephrolithiasis	6.54e-05	0.00281	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—ADCY10—nephrolithiasis	6.5e-05	0.00279	CbGpPWpGaD
Pazopanib—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	6.5e-05	0.00279	CbGpPWpGaD
Pazopanib—KIT—Signaling by PDGF—SPP1—nephrolithiasis	6.42e-05	0.00276	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	6.39e-05	0.00274	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	6.39e-05	0.00274	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—RGS14—nephrolithiasis	6.34e-05	0.00273	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—ADCY10—nephrolithiasis	6.2e-05	0.00266	CbGpPWpGaD
Pazopanib—KDR—Extracellular matrix organization—SPP1—nephrolithiasis	6.15e-05	0.00264	CbGpPWpGaD
Pazopanib—FGFR3—Disease—ATP6V0A4—nephrolithiasis	6.12e-05	0.00263	CbGpPWpGaD
Pazopanib—FGFR1—Signaling by PDGF—SPP1—nephrolithiasis	6.1e-05	0.00262	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling by PDGF—SPP1—nephrolithiasis	6.08e-05	0.00261	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—CHRM3—nephrolithiasis	5.94e-05	0.00255	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	5.94e-05	0.00255	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	5.94e-05	0.00255	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	5.91e-05	0.00254	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	5.91e-05	0.00254	CbGpPWpGaD
Pazopanib—PDGFRA—Focal Adhesion—SPP1—nephrolithiasis	5.87e-05	0.00252	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—SLC7A9—nephrolithiasis	5.84e-05	0.00251	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—DGKH—nephrolithiasis	5.84e-05	0.00251	CbGpPWpGaD
Pazopanib—FGF1—Disease—SLC26A1—nephrolithiasis	5.71e-05	0.00245	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—RGS14—nephrolithiasis	5.67e-05	0.00244	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.61e-05	0.00241	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—DGKH—nephrolithiasis	5.61e-05	0.00241	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—RGS14—nephrolithiasis	5.53e-05	0.00238	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	5.5e-05	0.00236	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	5.5e-05	0.00236	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling by PDGF—SPP1—nephrolithiasis	5.48e-05	0.00235	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—CHRM3—nephrolithiasis	5.44e-05	0.00234	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—PTH—nephrolithiasis	5.44e-05	0.00234	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	5.29e-05	0.00227	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	5.29e-05	0.00227	CbGpPWpGaD
Pazopanib—PDGFRB—Focal Adhesion—SPP1—nephrolithiasis	5.29e-05	0.00227	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—RGS14—nephrolithiasis	5.27e-05	0.00227	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	5.18e-05	0.00222	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	5.18e-05	0.00222	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ADCY10—nephrolithiasis	5.13e-05	0.00221	CbGpPWpGaD
Pazopanib—FGF1—Disease—ATP6V0A4—nephrolithiasis	5.09e-05	0.00219	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ADCY10—nephrolithiasis	5.04e-05	0.00217	CbGpPWpGaD
Pazopanib—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	5.02e-05	0.00216	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—PTH—nephrolithiasis	4.97e-05	0.00214	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	4.9e-05	0.00211	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	4.9e-05	0.00211	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ADCY10—nephrolithiasis	4.78e-05	0.00206	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ADCY10—nephrolithiasis	4.77e-05	0.00205	CbGpPWpGaD
Pazopanib—FGFR2—Disease—SLC26A1—nephrolithiasis	4.72e-05	0.00203	CbGpPWpGaD
Pazopanib—KIT—Disease—SLC26A1—nephrolithiasis	4.64e-05	0.00199	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	4.61e-05	0.00198	CbGpPWpGaD
Pazopanib—FGFR1—Disease—SLC26A1—nephrolithiasis	4.4e-05	0.00189	CbGpPWpGaD
Pazopanib—LCK—Signaling by PDGF—SPP1—nephrolithiasis	4.4e-05	0.00189	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—SLC26A1—nephrolithiasis	4.39e-05	0.00189	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—RGS14—nephrolithiasis	4.36e-05	0.00188	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ADCY10—nephrolithiasis	4.3e-05	0.00185	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.29e-05	0.00184	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—DGKH—nephrolithiasis	4.29e-05	0.00184	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—RGS14—nephrolithiasis	4.29e-05	0.00184	CbGpPWpGaD
Pazopanib—SLCO1B1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	4.23e-05	0.00182	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	4.22e-05	0.00181	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	4.22e-05	0.00181	CbGpPWpGaD
Pazopanib—FGFR2—Disease—ATP6V0A4—nephrolithiasis	4.21e-05	0.00181	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ADCY10—nephrolithiasis	4.21e-05	0.00181	CbGpPWpGaD
Pazopanib—KIT—Disease—ATP6V0A4—nephrolithiasis	4.13e-05	0.00178	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—RGS14—nephrolithiasis	4.07e-05	0.00175	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—RGS14—nephrolithiasis	4.06e-05	0.00174	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—CHRM3—nephrolithiasis	4.06e-05	0.00174	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—GRHPR—nephrolithiasis	4e-05	0.00172	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—SLC26A1—nephrolithiasis	3.95e-05	0.0017	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—SPP1—nephrolithiasis	3.94e-05	0.00169	CbGpPWpGaD
Pazopanib—FGFR1—Disease—ATP6V0A4—nephrolithiasis	3.92e-05	0.00169	CbGpPWpGaD
Pazopanib—ABCG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	3.92e-05	0.00168	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—ATP6V0A4—nephrolithiasis	3.91e-05	0.00168	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.83e-05	0.00165	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—DGKH—nephrolithiasis	3.83e-05	0.00165	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.73e-05	0.0016	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—DGKH—nephrolithiasis	3.73e-05	0.0016	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—PTH—nephrolithiasis	3.71e-05	0.00159	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—GRHPR—nephrolithiasis	3.67e-05	0.00158	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—RGS14—nephrolithiasis	3.65e-05	0.00157	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—RGS14—nephrolithiasis	3.58e-05	0.00154	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AGXT—nephrolithiasis	3.57e-05	0.00153	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.56e-05	0.00153	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—DGKH—nephrolithiasis	3.56e-05	0.00153	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—ATP6V0A4—nephrolithiasis	3.52e-05	0.00151	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ADCY10—nephrolithiasis	3.45e-05	0.00148	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—GRHPR—nephrolithiasis	3.4e-05	0.00146	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AGXT—nephrolithiasis	3.27e-05	0.00141	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	3.2e-05	0.00137	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	3.2e-05	0.00137	CbGpPWpGaD
Pazopanib—LCK—Disease—SLC26A1—nephrolithiasis	3.17e-05	0.00136	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CHRM3—nephrolithiasis	3.1e-05	0.00133	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—SLC26A1—nephrolithiasis	3.03e-05	0.0013	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—APRT—nephrolithiasis	3.03e-05	0.0013	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AGXT—nephrolithiasis	3.03e-05	0.0013	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	2.97e-05	0.00128	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	2.97e-05	0.00128	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.95e-05	0.00127	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—DGKH—nephrolithiasis	2.95e-05	0.00127	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RGS14—nephrolithiasis	2.93e-05	0.00126	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.89e-05	0.00124	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—DGKH—nephrolithiasis	2.89e-05	0.00124	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PTH—nephrolithiasis	2.83e-05	0.00122	CbGpPWpGaD
Pazopanib—LCK—Disease—ATP6V0A4—nephrolithiasis	2.83e-05	0.00122	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—SLC26A1—nephrolithiasis	2.78e-05	0.0012	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—APRT—nephrolithiasis	2.78e-05	0.0012	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CHRM3—nephrolithiasis	2.77e-05	0.00119	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—DGKH—nephrolithiasis	2.75e-05	0.00118	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.75e-05	0.00118	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.74e-05	0.00118	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—DGKH—nephrolithiasis	2.74e-05	0.00118	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—SPP1—nephrolithiasis	2.73e-05	0.00117	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CHRM3—nephrolithiasis	2.7e-05	0.00116	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	2.65e-05	0.00114	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	2.65e-05	0.00114	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—APRT—nephrolithiasis	2.57e-05	0.00111	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—SLC26A1—nephrolithiasis	2.57e-05	0.00111	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CHRM3—nephrolithiasis	2.57e-05	0.00111	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PTH—nephrolithiasis	2.53e-05	0.00109	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—SPP1—nephrolithiasis	2.5e-05	0.00107	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PTH—nephrolithiasis	2.47e-05	0.00106	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—DGKH—nephrolithiasis	2.47e-05	0.00106	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.47e-05	0.00106	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.42e-05	0.00104	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—DGKH—nephrolithiasis	2.42e-05	0.00104	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PTH—nephrolithiasis	2.35e-05	0.00101	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AQP1—nephrolithiasis	2.16e-05	0.000929	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CHRM3—nephrolithiasis	2.13e-05	0.000916	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	2.12e-05	0.00091	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GRHPR—nephrolithiasis	2.11e-05	0.000906	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CHRM3—nephrolithiasis	2.09e-05	0.000899	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CHRM3—nephrolithiasis	1.99e-05	0.000854	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AQP1—nephrolithiasis	1.98e-05	0.000852	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CHRM3—nephrolithiasis	1.98e-05	0.000851	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ATP6V0A4—nephrolithiasis	1.98e-05	0.000851	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—DGKH—nephrolithiasis	1.98e-05	0.000851	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—CHRM3—nephrolithiasis	1.96e-05	0.00084	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTH—nephrolithiasis	1.95e-05	0.000838	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTH—nephrolithiasis	1.91e-05	0.000823	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AGXT—nephrolithiasis	1.88e-05	0.000808	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—SPP1—nephrolithiasis	1.86e-05	0.0008	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GRHPR—nephrolithiasis	1.84e-05	0.000789	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AQP1—nephrolithiasis	1.83e-05	0.000788	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTH—nephrolithiasis	1.82e-05	0.000781	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTH—nephrolithiasis	1.81e-05	0.000779	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—CHRM3—nephrolithiasis	1.79e-05	0.00077	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CHRM3—nephrolithiasis	1.78e-05	0.000767	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CHRM3—nephrolithiasis	1.75e-05	0.000751	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GRHPR—nephrolithiasis	1.73e-05	0.000744	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—CHRM3—nephrolithiasis	1.66e-05	0.000713	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AGXT—nephrolithiasis	1.64e-05	0.000704	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTH—nephrolithiasis	1.63e-05	0.000701	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTH—nephrolithiasis	1.6e-05	0.000687	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APRT—nephrolithiasis	1.6e-05	0.000687	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	1.6e-05	0.000687	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AGXT—nephrolithiasis	1.54e-05	0.000663	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GRHPR—nephrolithiasis	1.47e-05	0.00063	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CHRM3—nephrolithiasis	1.43e-05	0.000615	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—SPP1—nephrolithiasis	1.42e-05	0.000611	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—SLC26A1—nephrolithiasis	1.39e-05	0.000598	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APRT—nephrolithiasis	1.39e-05	0.000598	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APRT—nephrolithiasis	1.31e-05	0.000564	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	1.31e-05	0.000564	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTH—nephrolithiasis	1.31e-05	0.000563	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AGXT—nephrolithiasis	1.31e-05	0.000562	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—SPP1—nephrolithiasis	1.27e-05	0.000546	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—SPP1—nephrolithiasis	1.24e-05	0.000533	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—SPP1—nephrolithiasis	1.18e-05	0.000508	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AQP1—nephrolithiasis	1.14e-05	0.000489	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GRHPR—nephrolithiasis	1.13e-05	0.000486	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APRT—nephrolithiasis	1.11e-05	0.000478	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	1.11e-05	0.000478	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CHRM3—nephrolithiasis	1.03e-05	0.000443	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AGXT—nephrolithiasis	1.01e-05	0.000434	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AQP1—nephrolithiasis	9.92e-06	0.000426	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—SPP1—nephrolithiasis	9.78e-06	0.00042	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—SPP1—nephrolithiasis	9.61e-06	0.000413	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AQP1—nephrolithiasis	9.35e-06	0.000402	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SPP1—nephrolithiasis	9.12e-06	0.000392	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SPP1—nephrolithiasis	9.1e-06	0.000391	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CHRM3—nephrolithiasis	8.97e-06	0.000386	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APRT—nephrolithiasis	8.58e-06	0.000369	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	8.58e-06	0.000369	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CHRM3—nephrolithiasis	8.45e-06	0.000363	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SPP1—nephrolithiasis	8.19e-06	0.000352	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SPP1—nephrolithiasis	8.02e-06	0.000345	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AQP1—nephrolithiasis	7.92e-06	0.00034	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CHRM3—nephrolithiasis	7.16e-06	0.000308	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SPP1—nephrolithiasis	6.58e-06	0.000283	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AQP1—nephrolithiasis	6.11e-06	0.000263	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CHRM3—nephrolithiasis	5.53e-06	0.000238	CbGpPWpGaD
